nach oben

Journal of Neuro-Oncology

Erschienen in:

19.06.2020 | Topic Review

A systematic review and meta-analysis of supratotal versus gross total resection for glioblastoma

Erschienen in: Journal of Neuro-Oncology | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Due to the infiltrative nature of glioblastoma (GBM) outside of the contrast-enhancing region on MRI, there is interest in exploring supratotal resections (SpTR) that extend beyond the contrast-enhancing portion of the tumor. However, there is currently no consensus on the potential survival benefit of SpTR in GBM compared to gross total resection (GTR). In this study, we compare the impact of SpTR versus GTR on overall survival (OS) of GBM patients.

Methods

We performed a systematic review and meta-analysis of literature published on PubMed, Embase, The Cochrane Library, Web of Science, Scopus, and ClinicalTrials.gov, from inception to August 16, 2018, to identify articles comparing OS after SpTR versus GTR.

Results

We identified 8902 unique citations, of which 11 articles met study inclusion criteria. 810 patients underwent SpTR out of a total of 2056 patients. 9 of 11 studies demonstrated improved outcomes with SpTR compared to GTR (median improvement in OS of 10.5 months), with no significant difference in postoperative complication rate. Overall study quality was variable, with ten studies presenting level IV evidence and one study presenting level IIIb evidence. Subgroup meta-analysis based on SpTR definition demonstrated a statistically significant 35% lower risk of mortality in patients who underwent anatomical SpTR compared to patients who underwent GTR (Hazard ratio = 0.65, 95% CI 0.47- 0.91, p = 0.003).

Conclusion

Our systematic review indicates SpTR may be associated with improved OS compared to GTR for GBM, especially with anatomical SpTR. However, this is limited by variable study design and significant clinical and methodological heterogeneity among studies. There is need for prospective clinical data to further guide parameters regarding the use of SpTR in GBM.

Nur mit Berechtigung zugänglich

Omuro A, DeAngelis LM (2013) Glioblastoma and other malignant gliomas: a clinical review. JAMA—J Am Med Assoc 310:1842–1850CrossRef

Brada M, Hoang-Xuan K, Rampling R et al (2014) Glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 61:e9–e16. https://doi.org/10.1007/s10517-015-2864-2CrossRef

Sanai N, Berger MS (2008) Glioma extent of resection and methods. Neurosurgery 62:753–766. https://doi.org/10.1227/01.NEU.0000310769.20996.BDCrossRefPubMed

Lacroix M, Abi-Said D, Fourney DR et al (2001) A multivariate analysis of 416 patients with glioblastoma multiforme: Prognosis, extent of resection, and survival. J Neurosurg 95:190–198. https://doi.org/10.3171/jns.2001.95.2.0190CrossRefPubMed

Brown TJ, Brennan MC, Li M et al (2016) Association of the extent of resection with survival in glioblastoma a systematic review and meta-Analysis. JAMA Oncol 2:1460–1469. https://doi.org/10.1001/jamaoncol.2016.1373CrossRefPubMedPubMedCentral

Sanai N, Polley M-Y, McDermott MW et al (2011) An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg 115:3–8. https://doi.org/10.3171/2011.2.JNS10998CrossRefPubMed

Li YM, Suki D, Hess K, Sawaya R (2016) The influence of maximum safe resection of glioblastoma on survival in 1229 patients: can we do better than gross-total resection? J Neurosurg 124:977–988. https://doi.org/10.3171/2015.5.JNS142087CrossRefPubMed

Dandy WE (1928) Removal of right cerebral hemisphere for certain tumors with hemiplegia: preliminary report. J Am Med Assoc 90:823–825. https://doi.org/10.1001/jama.1928.02690380007003CrossRef

Baldock AL, Ahn S, Rockne R et al (2014) Patient-specific metrics of invasiveness reveal significant prognostic benefit of resection in a predictable subset of gliomas. PLoS ONE 9:e99057. https://doi.org/10.1371/journal.pone.0099057CrossRefPubMedPubMedCentral

10.

Darmanis S, Sloan SA, Croote D et al (2017) Single-cell RNA-Seq analysis of infiltrating neoplastic cells at the migrating front of human glioblastoma. Cell Rep 21:1399–1410. https://doi.org/10.1016/j.celrep.2017.10.030CrossRefPubMedPubMedCentral

11.

Eyüpoglu IY, Buchfelder M, Savaskan NE (2013) Surgical resection of malignant gliomas-role in optimizing patient outcome. Nat Rev Neurol 9:141–151CrossRefPubMed

12.

Eidel O, Burth S, Neumann JO et al (2017) Tumor infiltration in enhancing and non-enhancing parts of glioblastoma: a correlation with histopathology. PLoS ONE. https://doi.org/10.1371/journal.pone.0169292CrossRefPubMedPubMedCentral

13.

Giese A, Bjerkvig R, Berens ME, Westphal M (2003) Cost of migration: invasion of malignant gliomas treatment. J Clin Oncol 21:1624–1636. https://doi.org/10.1200/JC0.2003.05.063CrossRefPubMed

14.

Rahman M, Abbatematteo J, De Leo EK et al (2017) The effects of new or worsened postoperative neurological deficits on survival of patients with glioblastoma. J Neurosurg 127:123–131. https://doi.org/10.3171/2016.7.JNS16396CrossRefPubMed

15.

McGirt MJ, Mukherjee D, Chaichana KL et al (2009) Association of surgically acquired motor and language deficits on overall survival after resection of glioblastoma multiforme. Neurosurgery 65:463–469. https://doi.org/10.1227/01.NEU.0000349763.42238.E9CrossRefPubMed

16.

De Leeuw CN, Vogelbaum MA (2019) Supratotal resection in glioma: a systematic review. Neuro Oncol 21:179–188. https://doi.org/10.1093/neuonc/noy166CrossRefPubMed

17.

Incekara F, Koene S, Vincent AJPE et al (2019) Association between supratotal glioblastoma resection and patient survival: a systematic review and meta-analysis. World Neurosurg 127:617–624.e2CrossRefPubMed

18.

Liberati A, Altman DG, Tetzlaff J, et al. (2009). The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med, 6

19.

Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the prisma statement. PLoS Med 6:e1000097. https://doi.org/10.1371/journal.pmed.1000097CrossRefPubMedPubMedCentral

20.

Covidence—Better systematic review management

21.

OCEBM Levels of Evidence—CEBM. https://www.cebm.net/index.aspx?o=5653

22.

Guyot P, Ades AE, Ouwens MJNM, Welton NJ (2012) Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. https://doi.org/10.1186/1471-2288-12-9CrossRefPubMedPubMedCentral

23.

Liu Z, Rich B, Hanley JA (2015) Recovering the raw data behind a non-parametric survival curve. Syst Rev. https://doi.org/10.1186/2046-4053-3-151CrossRef

24.

Higgins JPT, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539–1558. https://doi.org/10.1002/sim.1186CrossRefPubMed

25.

Glenn CA, Baker CM, Conner AK et al (2018) An examination of the role of supramaximal resection of temporal lobe glioblastoma multiforme. World Neurosurg 114:e747–e755. https://doi.org/10.1016/j.wneu.2018.03.072CrossRefPubMed

26.

Esquenazi Y, Friedman E, Liu Z et al (2017) The Survival advantage of “supratotal” resection of glioblastoma using selective cortical mapping and the subpial technique. Neurosurgery 81:275–288. https://doi.org/10.1093/neuros/nyw174CrossRefPubMed

27.

Grabowski MM, Recinos PF, Nowacki AS et al (2014) Residual tumor volume versus extent of resection: predictors of survival after surgery for glioblastoma. J Neurosurg 121:1115–1123. https://doi.org/10.3171/2014.7.JNS132449CrossRefPubMed

28.

Mampre D, Ehresman J, Pinilla-Monsalve G et al (2018) Extending the resection beyond the contrast-enhancement for glioblastoma: feasibility, efficacy, and outcomes. Br J Neurosurg 32:528–535. https://doi.org/10.1080/02688697.2018.1498450CrossRefPubMed

29.

De Bonis P, Anile C, Pompucci A et al (2013) The influence of surgery on recurrence pattern of glioblastoma. Clin Neurol Neurosurg 115:37–43. https://doi.org/10.1016/j.clineuro.2012.04.005CrossRefPubMed

30.

Pessina F, Navarria P, Cozzi L et al (2017) Maximize surgical resection beyond contrast-enhancing boundaries in newly diagnosed glioblastoma multiforme: is it useful and safe? A single institution retrospective experience. J Neurooncol 135:129–139. https://doi.org/10.1007/s11060-017-2559-9CrossRefPubMed

31.

Hamada S, Abou-Zeid A (2016) Anatomical resection in glioblastoma: extent of resection and its impact on duration of survival. Egypt J Neurol Psychiatry Neurosurg. https://doi.org/10.4103/1110-1083.192655CrossRef

32.

Eypoglu IY, Hore N, Merkel A et al (2016) Supra-complete surgery via dual intraoperative visualization approach (DiVA) prolongs patient survival in glioblastoma. Oncotarget 7:25755–25768CrossRef

33.

Aldave G, Tejada S, Pay E et al (2013) Prognostic value of residual fluorescent tissue in glioblastoma patients after gross total resection in 5-aminolevulinic acid-guided surgery. Neurosurgery 72:915–920. https://doi.org/10.1227/NEU.0b013e31828c3974CrossRefPubMed

34.

Grossman R, Shimony N, Shir D et al (2017) Dynamics of FLAIR volume changes in glioblastoma and prediction of survival. Ann Surg Oncol 24:794–800. https://doi.org/10.1245/s10434-016-5635-zCrossRefPubMed

35.

Binabaj MM, Bahrami A, ShahidSales S et al (2018) The prognostic value of MGMT promoter methylation in glioblastoma: a meta-analysis of clinical trials. J Cell Physiol 233:378–386. https://doi.org/10.1002/jcp.25896CrossRefPubMed

36.

Chen JR, Yao Y, Xu HZ, Qin ZY (2016) Isocitrate dehydrogenase (IDH)1/2 mutations as prognostic markers in patients with glioblastomas. Med (United States) 95:e2583. https://doi.org/10.1097/MD.0000000000002583CrossRef

37.

Yang P, Zhang W, Wang Y et al (2015) IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry. Oncotarget 6:40896–40906CrossRefPubMedPubMedCentral

38.

Zou P, Xu H, Chen P et al (2013) IDH1/IDH2 mutations define the prognosis and molecular profiles of patients with gliomas: a meta-analysis. PLoS ONE 8:e68782. https://doi.org/10.1371/journal.pone.0068782CrossRefPubMedPubMedCentral

39.

Beiko J, Suki D, Hess KR et al (2014) IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. Neuro Oncol 16:81–91. https://doi.org/10.1093/neuonc/not159CrossRefPubMed

40.

Chaichana K, Zadnik P, Weingart J et al (2013) Multiple resections for patients with glioblastoma: prolonging survival. J Neurosurg 118(4):812–920. https://doi.org/10.3171/2012.0.JNS1277CrossRefPubMed

41.

Perrini P, Gambacciani C, Weiss A et al (2017) Survival outcomes following repeat surgery for recurrent glioblastoma: a single-center retrospective analysis. J Neurooncol 131(3):585–591. https://doi.org/10.1007/s11060-016-2330-7CrossRefPubMed

Titel: A systematic review and meta-analysis of supratotal versus gross total resection for glioblastoma
Publikationsdatum: 19.06.2020
Erschienen in: Journal of Neuro-Oncology / Ausgabe 3/2020
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-020-03556-y

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2020

Management of incidental anterior skull base large and giant meningiomas in elderly patients

Children with DIPG and high-grade glioma treated with temozolomide, irinotecan, and bevacizumab: the Seattle Children’s Hospital experience

Reduced-dose craniospinal irradiation is feasible for standard-risk adult medulloblastoma patients

Diagnostic delay and outcome in immunocompetent patients with primary central nervous system lymphoma in Spain: a multicentric study

Prescription of memantine during non-stereotactic, brain-directed radiation among patients with brain metastases: a population-based study